Cargando…
SARS-CoV-2 Antinucleocapsid Antibody Response of mRNA and Inactivated Virus Vaccines Compared to Unvaccinated Individuals
Comparative studies of SARS-CoV-2 antinucleocapsid (anti-N) antibody response in the context of inactivated virus vaccines versus natural infection are limited. This study aims to determine and compare the anti-N antibody levels in people vaccinated with Sinopharm’s (Wuhan, China) inactivated virus...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143597/ https://www.ncbi.nlm.nih.gov/pubmed/35632399 http://dx.doi.org/10.3390/vaccines10050643 |
_version_ | 1784715845172199424 |
---|---|
author | Qaqish, Arwa Abbas, Manal Mohammad Al-Tamimi, Mohammad Abbas, Manal Ahmad Al-Omari, Mariam Alqassieh, Rami |
author_facet | Qaqish, Arwa Abbas, Manal Mohammad Al-Tamimi, Mohammad Abbas, Manal Ahmad Al-Omari, Mariam Alqassieh, Rami |
author_sort | Qaqish, Arwa |
collection | PubMed |
description | Comparative studies of SARS-CoV-2 antinucleocapsid (anti-N) antibody response in the context of inactivated virus vaccines versus natural infection are limited. This study aims to determine and compare the anti-N antibody levels in people vaccinated with Sinopharm’s (Wuhan, China) inactivated virus vaccine in comparison with naturally infected unvaccinated and Pfizer’s spike (S) mRNA-based vaccinated subjects. Two hundred ninety-nine Jordanian adults participated in the study including unvaccinated COVID-19-infected patients (n = 99), Pfizer-vaccinated (n = 100), and Sinopharm-vaccinated recipients (n = 100). Serum samples were assayed for anti-N IgG, anti-N IgM, and anti-S IgG. Sera of 64.6% of naturally infected unvaccinated participants had positive anti-S IgG (median = 36.35 U/mL; range: 0.04–532.5 U/mL) compared to 88% of Pfizer-vaccinated (Manhattan, NY, USA) (median = 26.52 U/mL; range: 0.39–1265 U/mL) and 58% of Sinopharm-vaccinated subjects (median = 14.35 U/mL; range: 0.39–870.17 U/mL). Samples of 60.6% of naturally infected unvaccinated people had positive anti-N IgG (median = 15.03 U/mL; range: 0–265.1 U/mL) compared to 25% of Pfizer-vaccinated (median = 0.02 U/mL; range: 0–68 U/mL) and 48% of Sinopharm-vaccinated subjects (median = 0.8 U/mL; range: 0–146.3 U/mL). Anti-N titers among the three groups were significantly different (p < 0.05). Anti-N IgM antibodies appeared in 23.2% of the naturally infected unvaccinated group (median = 0.29 U/mL; range: 0–15 U/mL) compared to only 9.0% of Pfizer-vaccinated (median = 018 U/mL; range: 0–33 U/mL) and 7.0% of Sinopharm-vaccinated subjects (median = 0.2 U/mL; range: 0–12.02 U/mL). A significant negative correlation was found between anti-S and age for both vaccines and between anti-S and the presence of chronic disease in Sinopharm-vaccinated subjects. A significant positive correlation between anti-N and anti-S titers was found among the three groups. This study shows that the inactivated virus vaccine, Sinopharm, induces an anti-N response that can boost that of natural infection or vice versa. On the other hand, the Pfizer mRNA-based vaccine induces a significantly stronger anti-S Ab response. |
format | Online Article Text |
id | pubmed-9143597 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91435972022-05-29 SARS-CoV-2 Antinucleocapsid Antibody Response of mRNA and Inactivated Virus Vaccines Compared to Unvaccinated Individuals Qaqish, Arwa Abbas, Manal Mohammad Al-Tamimi, Mohammad Abbas, Manal Ahmad Al-Omari, Mariam Alqassieh, Rami Vaccines (Basel) Article Comparative studies of SARS-CoV-2 antinucleocapsid (anti-N) antibody response in the context of inactivated virus vaccines versus natural infection are limited. This study aims to determine and compare the anti-N antibody levels in people vaccinated with Sinopharm’s (Wuhan, China) inactivated virus vaccine in comparison with naturally infected unvaccinated and Pfizer’s spike (S) mRNA-based vaccinated subjects. Two hundred ninety-nine Jordanian adults participated in the study including unvaccinated COVID-19-infected patients (n = 99), Pfizer-vaccinated (n = 100), and Sinopharm-vaccinated recipients (n = 100). Serum samples were assayed for anti-N IgG, anti-N IgM, and anti-S IgG. Sera of 64.6% of naturally infected unvaccinated participants had positive anti-S IgG (median = 36.35 U/mL; range: 0.04–532.5 U/mL) compared to 88% of Pfizer-vaccinated (Manhattan, NY, USA) (median = 26.52 U/mL; range: 0.39–1265 U/mL) and 58% of Sinopharm-vaccinated subjects (median = 14.35 U/mL; range: 0.39–870.17 U/mL). Samples of 60.6% of naturally infected unvaccinated people had positive anti-N IgG (median = 15.03 U/mL; range: 0–265.1 U/mL) compared to 25% of Pfizer-vaccinated (median = 0.02 U/mL; range: 0–68 U/mL) and 48% of Sinopharm-vaccinated subjects (median = 0.8 U/mL; range: 0–146.3 U/mL). Anti-N titers among the three groups were significantly different (p < 0.05). Anti-N IgM antibodies appeared in 23.2% of the naturally infected unvaccinated group (median = 0.29 U/mL; range: 0–15 U/mL) compared to only 9.0% of Pfizer-vaccinated (median = 018 U/mL; range: 0–33 U/mL) and 7.0% of Sinopharm-vaccinated subjects (median = 0.2 U/mL; range: 0–12.02 U/mL). A significant negative correlation was found between anti-S and age for both vaccines and between anti-S and the presence of chronic disease in Sinopharm-vaccinated subjects. A significant positive correlation between anti-N and anti-S titers was found among the three groups. This study shows that the inactivated virus vaccine, Sinopharm, induces an anti-N response that can boost that of natural infection or vice versa. On the other hand, the Pfizer mRNA-based vaccine induces a significantly stronger anti-S Ab response. MDPI 2022-04-20 /pmc/articles/PMC9143597/ /pubmed/35632399 http://dx.doi.org/10.3390/vaccines10050643 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Qaqish, Arwa Abbas, Manal Mohammad Al-Tamimi, Mohammad Abbas, Manal Ahmad Al-Omari, Mariam Alqassieh, Rami SARS-CoV-2 Antinucleocapsid Antibody Response of mRNA and Inactivated Virus Vaccines Compared to Unvaccinated Individuals |
title | SARS-CoV-2 Antinucleocapsid Antibody Response of mRNA and Inactivated Virus Vaccines Compared to Unvaccinated Individuals |
title_full | SARS-CoV-2 Antinucleocapsid Antibody Response of mRNA and Inactivated Virus Vaccines Compared to Unvaccinated Individuals |
title_fullStr | SARS-CoV-2 Antinucleocapsid Antibody Response of mRNA and Inactivated Virus Vaccines Compared to Unvaccinated Individuals |
title_full_unstemmed | SARS-CoV-2 Antinucleocapsid Antibody Response of mRNA and Inactivated Virus Vaccines Compared to Unvaccinated Individuals |
title_short | SARS-CoV-2 Antinucleocapsid Antibody Response of mRNA and Inactivated Virus Vaccines Compared to Unvaccinated Individuals |
title_sort | sars-cov-2 antinucleocapsid antibody response of mrna and inactivated virus vaccines compared to unvaccinated individuals |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143597/ https://www.ncbi.nlm.nih.gov/pubmed/35632399 http://dx.doi.org/10.3390/vaccines10050643 |
work_keys_str_mv | AT qaqisharwa sarscov2antinucleocapsidantibodyresponseofmrnaandinactivatedvirusvaccinescomparedtounvaccinatedindividuals AT abbasmanalmohammad sarscov2antinucleocapsidantibodyresponseofmrnaandinactivatedvirusvaccinescomparedtounvaccinatedindividuals AT altamimimohammad sarscov2antinucleocapsidantibodyresponseofmrnaandinactivatedvirusvaccinescomparedtounvaccinatedindividuals AT abbasmanalahmad sarscov2antinucleocapsidantibodyresponseofmrnaandinactivatedvirusvaccinescomparedtounvaccinatedindividuals AT alomarimariam sarscov2antinucleocapsidantibodyresponseofmrnaandinactivatedvirusvaccinescomparedtounvaccinatedindividuals AT alqassiehrami sarscov2antinucleocapsidantibodyresponseofmrnaandinactivatedvirusvaccinescomparedtounvaccinatedindividuals |